Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603882's 5-Year Yield-on-Cost % is ranked better than 93.55% of 62
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.435
vs SHSE:603882: 18.07
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Guangzhou Kingmed Diagnostics Group Co 5-Year Yield-on-Cost % Related Terms
SHSE:603882 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Kingmed Diagnostics Group Co 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's 5-Year Yield-on-Cost % falls into.
Guangzhou Kingmed Diagnostics Group Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a 5-Year Yield-on-Cost % of 18.07 as of Aug. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. This is 103% above median its historical median of 8.91. Over the past decade, Guangzhou Kingmed Diagnostics Group Co's 5-Year Yield-on-Cost % has ranged from 0.49 to 39.72. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #4 out of 62 companies in the Medical Diagnostics & Research industry, placing it in the top 6.5%.
Is Guangzhou Kingmed Diagnostics Group Co's 5-Year Yield-on-Cost % too high?
Guangzhou Kingmed Diagnostics Group Co's current 5-Year Yield-on-Cost % of 18.07 is 103% above median its 10-year median of 8.91. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 39.72. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.44. Guangzhou Kingmed Diagnostics Group Co's value of 18.07 is 642.1% above this industry median. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #4 out of 62 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #4 out of 62 companies for 5-Year Yield-on-Cost %. This places Guangzhou Kingmed Diagnostics Group Co in the top 7% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.44. Guangzhou Kingmed Diagnostics Group Co's value of 18.07 is 642.1% above this benchmark. Historically, Guangzhou Kingmed Diagnostics Group Co's own 5-Year Yield-on-Cost % has ranged from 0.49 to 39.72 over the past decade. While the company's 10-year median is 8.91 vs. the industry median of 2.44, Guangzhou Kingmed Diagnostics Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.44, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Kingmed Diagnostics Group Co's current 5-Year Yield-on-Cost % of 18.07 is 642.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Kingmed Diagnostics Group Co's current 5-Year Yield-on-Cost % is 18.07, which is 103% above median its own 10-year median of 8.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.19, compared to a current price of ¥29.73 — trading 5.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 18.07, which is 103% above median its 10-year median of 8.91 and 642.1% above the Medical Diagnostics & Research industry median of 2.44. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 75/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current 5-Year Yield-on-Cost % is 18.07 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be overvalued.
The current stock price of ¥29.73 is trading 5.5% above its estimated GF Value™ of ¥28.19.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
5-Year Yield-on-Cost %: 18.07 (103% above median its 10-year median of 8.91)
GF Value™: ¥28.19 vs. price of ¥29.73 (5.5% above fair value)
Industry Position: 642.1% above the Medical Diagnostics & Research median (#4 of 62)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
75GF Score
Get the complete analysis for SHSE:603882
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
